Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in management of peritoneal carcinomatosis: Single center experience in Korea
- Author:
Hee Ju LEE
1
;
HyungJoo BAIK
;
Yo Han PARK
;
Sang Hyuk SEO
;
Kwang Hee KIM
;
Ki Beom BAE
;
Kwan Hee HONG
;
Ki Hyang KIM
;
Jung Mi BYUN
;
Dae Hoon JEONG
;
Kyung Bok LEE
;
Min Kyung OH
;
Kwang Rae CHO
;
Min Sung AN
Author Information
- Publication Type:Original Article
- Keywords: Peritoneal carcinomatosis; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy
- MeSH: Carcinoma; Drug Therapy; Humans; Korea; Mortality; Postoperative Complications; Retrospective Studies; Risk Factors
- From: Korean Journal of Clinical Oncology 2019;15(2):61-67
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Peritoneal carcinomatosis (PC) has been considered a terminal condition and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIEPC) is regarded as an alternative therapeutic option. This study aimed to evaluate the 30-day clinical outcomes of CRS/HIPEC and the feasibility of the surgery by investigating the morbidity and mortality in Inje University Hospital.METHODS: Data were retrospectively collected from 19 patients with PC who underwent CRS/HIPEC at Inje University Hospital in 2018. We evaluated pre-, intra-operative parameters and postoperative clinical outcomes and early complications.RESULTS: The mean operating time was 506.95 minutes and the mean blood loss was 837.11 mL. Six cases (31.58%) had morbidity of grade III or above. A longer operating time (≥560 minutes, P=0.038) and large blood loss (≥700 mL, P=0.060) were positively correlated with grade III or worse postoperative complications.CONCLUSION: Our early experience with CRS/HIPEC resulted in a 31.58% morbidity rate of grade III and above, with risk factors being longer operating time and greater intraoperative blood loss. As the surgical team's skills improve, a shorter operating time with less intraoperative blood loss could result in better short-term outcomes of CRS/HIPEC.
